Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Rating of “Hold” from Brokerages

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have received a consensus recommendation of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $4.79.

MRNS has been the subject of several recent analyst reports. StockNews.com initiated coverage on Marinus Pharmaceuticals in a research report on Monday. They set a “hold” rating for the company. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 30th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Royal Bank of Canada dropped their price target on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research note on Friday, October 25th. Finally, LADENBURG THALM/SH SH lowered Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter worth approximately $28,000. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $34,000. AQR Capital Management LLC raised its holdings in Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Marinus Pharmaceuticals in the 2nd quarter worth $64,000. Finally, Values First Advisors Inc. raised its holdings in Marinus Pharmaceuticals by 501.8% in the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 52,257 shares during the period. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Price Performance

Shares of MRNS opened at $0.31 on Tuesday. The firm has a market cap of $17.00 million, a PE ratio of -0.12 and a beta of 1.26. The stock’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.31. Marinus Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $11.26.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.